<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A questionnaire was distributed in early 1996 to 160 leading European neurological, neuro-pediatric and neurosurgical centers to assess the present status of <z:e sem="disease" ids="C0026654" disease_type="Disease or Syndrome" abbrv="MYMY|MYMY1">Moyamoya disease</z:e> in Europe </plain></SENT>
<SENT sid="1" pm="."><plain>The response rate was 43% </plain></SENT>
<SENT sid="2" pm="."><plain>Information was obtained on a total of 168 patients, of whom 110 had presented before 1992, and 58 from 1993 onward </plain></SENT>
<SENT sid="3" pm="."><plain>82% of the patients were Caucasian </plain></SENT>
<SENT sid="4" pm="."><plain>In <z:hpo ids='HP_0000001'>all</z:hpo> other respects, the clinical findings were similar to those observed in Japan </plain></SENT>
<SENT sid="5" pm="."><plain>The present study yields an incidence of 0.3 patients per center per year, which is approximately one-tenth of the incidence in Japan </plain></SENT>
<SENT sid="6" pm="."><plain>Alongside these results, the history of the recognition and treatment of this disease in Europe is briefly discussed </plain></SENT>
</text></document>